January 8, 2021 09:25 AM ESTUpdated 03:32 PM
R&D
FDA+

FDA side­swipes Ne­oleukin with clin­i­cal hold on lead im­munother­a­py can­di­date, sends shares plum­met­ing

Kyle Blankenship

Nat­ur­al killer and CD8 T cells for on­col­o­gy have been a hotbed of in­vest­ment in re­cent years, with some Big Phar­ma play­ers dab­bling in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

A service from the Financial Times